Kornimate/medical-research-clean huggingface dataset:
evaluation of laparoscopic cholecystectomy and concomitant paraumbilical hernia repair

Conditions: Abdominal Disorder

Summary: umbilical hernia frequently accompanies cholelithiasis. it is possible to repair these hernias after completing cholecystectomy.

laparoscopy is a type of surgical procedure that allows a surgeon to access the inside of the abdomen and pelvis without having to make large incisions in the skin. the use of laparoscopy in abdominal surgeries increases for its great benefits over open surgery as: 1)faster recovery, 2)shorter hospital stays 3)decrease blood loss, 4)decreased postoperative pain 5)earlier return to work and resumption of normal daily activity as well as, 6)cosmetic benefits. few studies discuss the efficacy and safety of using laparoscopy in management of lap cholecyctectomy and concomitant paraumbilical hernia repair

Eligibility criteria:
inclusion criteria: * any age, any sex of patients with chronic calcular cholecystitis associated with para-umbilical hernia exclusion criteria: * patients with associated diseases such as chronic pulmonary disease, cardiac disease, chronic renal failure. patients with strangulated para-umbilical hernia patients with recurrent paraumbilical hernia
aerobic exercises on persisted post burn anemia

Conditions: Burns

Summary: fourty patients who have total body surface area ranged from 20% to 35% of burn, anemic and 8th to 16th week post burn will participate in this study, the patients will be randomly divided into two equal groups (20 patients for each group): group a (experimental group) (aerobic exercise and medical treatment): group b ( control group) (medical treatment group):


Eligibility criteria:
inclusion criteria: the subject selection will be according to the following criteria: 1. ages of patients will be ranged from 20 to 35 years. 2. all patients underwent severe burn with tbsa ranged from 20% to 35%. 3. 8 th to 16th week post burn. 4. all patients will be referred with persisted anemia by a surgeon before starting the study procedure. 5. all patients will enter the study having their informed consent exclusion criteria: the potential participants will be excluded if they meet one of the following criteria: 16 1. patients with persisted pre burn anemia associated with systematic chronic disease such as coronary artery disease or chronic kidney disease. 2. patients with pre burn persisted anemia associated with autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus ,vasculitis, sarcoidosis, inflammatory bowel disease (ibd). 3. unevaluated cardiac arrhythmia, chronic bronchitis, poorly controlled type 1 diabetes, extreme morbid obesity, extreme underweight body mass index less than 12, poorly controlled hypertension, poorly controlled seizure disorder, poorly controlled hyperthyroidism, orthopedic limitation as fracture, .
the role of spectral filtering in a spectrally adjustable ocular photosensitivity analyzer

Conditions: Photosensitivity

Summary: this is a 6-visit, single-center, non-dispensing, randomized, single-masked, 5×5 crossover study. subjects will participate in 6 scheduled over the duration of approximately 10.5 months.


Eligibility criteria:
inclusion criteria: * potential subjects must satisfy all of the following criteria to be enrolled in the study: 1. the subject must read and sign the informed consent form. 2. the subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. healthy adult males or females age ≥18 and ≤30 years of age. 4. normal color vision as measured using the ishihara 38-plate test. 5. normal stereopsis as measured by a suitable test. 6. auto-refraction must show a spherical component of -2.00 through +2.00 d, and a cylindrical component of 0.00 through 1.50 d. 7. the subject's distance refractive sphere must be between -2.00 and +2.00 d in each eye. 8. the subject's distance refractive cylinder must be ≤ 1.50 d in each eye. 9. the subject must have unaided distance snellen visual acuity of 20/200 or better for each eye. 10. the subject must have best corrected distance snellen visual acuity of 20/25 or better for each eye. exclusion criteria: * potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. currently pregnant or lactating (subjects who become pregnant during the study will be discontinued). 2. history of refractive surgery or other ocular surgery. 3. employee or immediate family member of an employee of clinical site (e.g., investigator, coordinator, technician). 4. subjects that participated in the pilot study cr-6318. 5. systemic conditions or the use of medications that the investigator believes will contraindicate participation in this study. 6. abnormal level 3 neuro-ophthalmology exam including crystalline lens clarity grade 3 or worse (lens opacities classification system). 7. any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the fda slit lamp classification scale.
development of pain related avoidance of movement questionnaire

Conditions: Musculoskeletal Pain; Low Back Pain; Back Pain

Summary: in recent studies, it has been shown that people may have avoidance of movement due to pain. however, there is no scale that evaluates avoidance of movement due to pain in musculoskeletal problems. the aim of this study is to develop a scale to measure how much pain-related movement and activity is avoided in individuals with musculoskeletal pain, and to examine the results of its clinical application.

approaches and methods to be applied in the research; * demographic information (age, gender, weight, height, pain location, pain duration and diagnose) form will be recorded. * creation of questionnaire items * reviewing of items/questions * patients who accept to fill out the questionnaire and who has complain of musculoskeletal pain will be asked to answer the questions. * editing the scale according to the answers * reliability and validity studies of the questionnaire * investigation of the results of applying the scale with clinical follow-up to compare results of pain-related avoidance of movement questionnaire following common used questionnaires are going to be used; * visual analogue scale (vas) * tampa kinesiophobia scale * oswestry low back pain and disability index-2.0 spss version 23 (spss inc, armonk, ny) program will be used in the analysis of the data.

Eligibility criteria:
inclusion criteria; * having agreed to fill out the questionnaire * having pain caused by problems related to the musculoskeletal system * not having any disability in performing activities of daily living exclusion criteria; * individuals who are not allowed to move due to pain * if they have undergone surgery, individuals who have inconveniences in moving due to surgery * individuals who have cognitive problems in completing the questionnaire

Keywords: musculoskeletal pain kinesiophobia questionnaire
dexamethasone intravitreal implant (ozurdex®) for recurrent vogt-koyanagi-harada (vkh) disease posterior uveitis

Conditions: Posterior Uveitis

Summary: vkh disease is a vision threatening condition.the investigators consider that ozurdex intravitreal implant is an effective line of treatment in recurrent vkh posterior uveitis.

baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done. procedure included intravitreal injection of dexamethasone implant 0.7 mg (ozurdex(®); allergan, inc, irvine, ca)

Eligibility criteria:
inclusion criteria: * recurrent vkh posterior uveitis exclusion criteria: * retinal pathology, other causes of posterior uveitis

Keywords: dexamethasone;vkh
culture-sensitive emotion regulation group therapy for traumatized refugees

Conditions: Trauma

Summary: there is a lack of studies on treatment effect in traumatised refugees. recent findings indicate that emotion regulation deficits play a key role in ptsd also among traumatized refugees and highlight the importance and potential directions for the development of an emotion regulation training for refugees. in this study, the investigators therefore want to examine the effectiveness of a new, transdiagnostic, cultural-sensitive group therapy, which systematically teaches specific emotion regulation strategies. participants will be randomly assigned to either the emotion regulation training, delivered in group format or a wait list control condition. the study takes place in cooperation with refugio munich, which is a treatment centre specialised in the treatment of traumatised refugees. clinicians will deliver the treatment to traumatized asylum seekers and refugees that report difficulties in emotion regulation. the investigators will examine if refugees and asylum seekers in the intervention group will show improvements in psychological symptoms, social functioning as well as in emotion regulation in comparison to a wait list control group which will receive the treatment after the intervention group has completed. the group therapy covers 14 sessions and has a cognitive-behavioural background. it focuses on conveying strategies to cope with intense feelings and the patients should gain a sense of self-efficacy and control over their trauma-relevant feelings and symptoms. qualified interpreters will be used in the assessments as well as group therapies.


Eligibility criteria:
inclusion criteria: * refugee or asylum seeker from afghanistan, speaking dari * reporting at least one traumatic event on a trauma list * reporting difficulties in emotion regulation * between the age of 15 and 21 years exclusion criteria: * psychosis * serious suicidal ideations * currently receiving psychotherapy elsewhere * serious dissociation

Keywords: trauma treatment refugees emotion regulation group therapy randomized controlled ptsd
efficacy of rtms in the treatment of patients with migraine

Conditions: Migraine

Summary: migraine is a condition thought to be related to cortical hyperexcitability. repetitive transcranial magnetic stimulation (rtms) can modulate the cortical excitability by means of long-term potentiation or long-term depression. this study will will test the safety and efficacy of rtms in the treatment of patients with migraine.


Eligibility criteria:
inclusion criteria: * age of 18-65 years * diagnosed as migraine (with or without aura) * more than 4 attacks per month for at least 3 months prior to study * no preventive medication used * must be able to sign permit exclusion criteria: * history of seizure or family history of seizures * women in pregnancy or breast-feeding * patient with medication overuse * patient with other medical, psychologic, or surgical illness * patient under preventive medications * prior rtms examination one month within

Keywords: migraine transcranial magnetic stimulation repetitive transcranial magnetic stimulation rtms
tap blocks vs. iv lidocaine for kidney transplants

Conditions: Postoperative Pain

Summary: this study will compare continuous intravenous lidocaine against single-injection transversus abdominis plane (tap) block as a modality for postoperative analgesia in kidney transplant surgery.

this study is a non-inferiority trial designed to assess the analgesic efficacy of an intravenous (iv) lidocaine infusion against single-injection transversus abdominis plane (tap) block in patients undergoing kidney transplant surgery. the investigators propose a study of 124 subjects randomized into two groups. the control group will receive a tap block. the study group will receive a continuous iv lidocaine infusion. the investigators hypothesize that there will be no statistically significant difference in postoperative opioid consumption between the two groups in the first 24 hours.

Eligibility criteria:
inclusion criteria: * kidney transplant recipient * \>18 years old * consent to participate exclusion criteria: * \<18 years old * refusal to participate * chronic opioid use * seizure disorder * allergy to local anesthestics * severe hepatic disease
the association between plasma metabolites and the risk, efficacy and prognosis in early breast cancer

Conditions: Breast Cancer

Summary: this study investigates plasma metabolites to clarify the relationship between these metabolites and breast cancer, aiming to identify valuable biomarkers. furthermore, by incorporating clinical information-such as cancer stage, type, treatment outcomes, and prognosis-into prospective studies, the research seeks to further examine the correlation between plasma metabolites, treatment efficacy, and prognosis.

compared to normal tissues, tumor tissues exhibit significant metabolic changes. consequently, tumor metabolic dysregulation is recognized as a novel marker of cancer. differential analysis of metabolic phenotypes has the potential to establish new patient stratification criteria and biomarkers that facilitate personalized therapy. breast cancer is the most prevalent malignant tumor among women. with advancements in metabolomics sequencing technology, an increasing number of researchers are focusing on the role of metabolomics in the diagnosis and treatment of breast cancer. it is important to note that the significance of individual metabolites in relation to breast cancer varies across studies; therefore, a standardized metabolic profile for assessing breast cancer risk has yet to be established. this project collected data from natural populations and breast cancer patients by analyzing plasma metabolites alongside clinical treatment information. the goals of this study are to explore the correlation between plasma metabolites and breast cancer, as well as to identify biomarkers that characterize therapeutic efficacy and prognosis.

Eligibility criteria:
inclusion criteria: * cohort 1 control group: women without breast cancer or other malignancies. case group: patients with histologically confirmed carcinoma in situ or invasive breast cancer; no prior treatment; no distant metastasis; and not associated with other malignant tumor diseases. * cohort 2 pathologically diagnosed as breast cancer; treatment niave patients; to receive standard neoadjuvant therapy; eastern cooperative oncology group (ecog) performance status of 0-1; presence of at least one measurable lesion according to the response evaluation criteria in advanced solid tumors version 1.1 (recist v1.1) . * cohort 3 patients who have been discharged after breast cancer treatment. exclusion criteria: * histologically undiagnosed breast cancer. breast cancer with distant metastases. combined with other malignant tumors. participants must not have participated in other clinical trials within the past month, unless those trials are observational or non-interventional in nature.

Keywords: metabolites breast cancer
treatment effects of escitalopram (lexapro®) on generalized anxiety disorder in patients with hiv and aids

Conditions: Anxiety Disorders; HIV Infections

Summary: the purpose of this study is to evaluate whether escitalopram is safe, well tolerated, and effective in the treatment of hiv-infected patients with generalized anxiety disorder.

anxiety disorders are twice as prevalent among hiv-infected patients as they are in the general population. approximately 25%-40% of hiv-infected patients have anxiety disorders; generalized anxiety disorder, panic disorder and post-traumatic stress disorder being the most frequent. non-adherence to anti-retroviral medications is commonly seen in patients with hiv with gad.the role of specific selective serotonin reuptake (ssris) in the treatment of hiv-patients with gad is unclear. escitalopram has been used in the treatment of gad in the general population. it has been shown to be safe in hiv-patients with a tolerable side-effect profile. however, whether it can improve gad in hiv-infected patients has not yet been investigated.

Eligibility criteria:
inclusion criteria: * age 18 to 65 years, * dsm-iv (diagnostic and statistical manual of mental disorders) criteria for generalized anxiety disorder * confirmed stable hiv disease and attending a hiv treatment program * stable dose of highly active anti-retroviral therapy for a minimum of 4 weeks * ability to give informed consent exclusion criteria: * bipolar disorders, any psychotic disorder * current major depression * substance dependence (except nicotine dependence) in the previous 3 months * currently suicidal or high suicide risk, serious or unstable medical disorders (e.g. uncontrolled hypertension or diabetes) * any hospitalization for hiv-related illness in the previous 3 months * any active cns (central nervous system) cns opportunistic infection or cns malignancies related to hiv * current active treatment for opportunistic infections related to hiv * any psychotropic drug treatment in the previous 2 weeks before screening * history of hypersensitivity to escitalopram and/or citalopram * admission bdi 23 * seizure disorder, traumatic brain injury * pregnant, nursing mother or planning to get pregnant. * concomitant mediations: at least 2-week washout of antidepressant (4 weeks for fluoxetine) or antipsychotic or anti-anxiety medications. * in the opinion of the investigator the clinical condition precludes participation in the trial.

Keywords: escitalopram anxiety disorder hiv and aids treatment experienced
search for structural variants in patients with dsd and inconclusive molecular diagnosis

Conditions: Disorder of Sex Development, 46,XY

Summary: the goal of this clinical trial is to identify structural variants by optical genome mapping (ogm) in the described participant population. the main questions it aims to answer are: * identify constitutional structural variants by ogm of dna extracted from blood leukocytes of patients with dsd for which the molecular diagnosis is inconclusive. * identify mosaic structural variants (present in a subpopulation of somatic cells only) by ogm of dna extracted from blood leukocytes of patients with dsd for which the molecular diagnosis is inconclusive. * compare the diagnostic yields of ogm and of comparative genome hybridization array (cgh array) methods. * compare the diagnostic yields of the ogm and of whole genome sequencing (national sequencing program), only if performed. participants will be required to: * a follow-up interview with a physician to review their own and family medical and surgical history, with a focusing on dsd. * an interview to assess their exposure to environmental pollutants during fetal life, using a validated questionnaire. * a blood test with a 5ml tube to perform optical genome mapping analysis.

patients with severe or moderate disorder of sex development (dsd) with a inconclusive molecular diagnosis will benefit from optical genome mapping analysis. a venous blood sample on ethylenediaminetetraacetic acid (edta) tube (5ml) will be taken in order to extract the dna that will be used for the optical genome mapping analysis.

Eligibility criteria:
inclusion criteria: * homogeneous xy male karyotype. * patient at least 6 months old * severe to moderate dsd (prader 1 to 5) for which the molecular diagnosis is inconclusive after a gene panel analysis. exclusion criteria: * subject with a homogeneous or mosaic xx, or monosomal x karyotype. * subject with an aneuploidy. * subject with a conclusive molecular diagnosis explaining the observed dsd (i.e. carrier of a causal genotype already well characterized by functional studies)
immune system stimulation by probiotic food supplementation

Conditions: Flu Symptom

Summary: the purpose of this study is to investigate the effects of a probiotic supplementation on adult volunteers with having caught the common cold more than 4 times in the past year. this study is a single center, double-blind, randomized, controlled, parallel-designed, prospective trial. subjects received a probiotic drink containing probiotics of lactobacillus paracasei (108 colony forming units (cfu)/ml), lactobacilluscasei431® (108cfu/ml) and lactobacillus fermentiumpcc® (106cfu/ml) or an identical placebo without probiotics for a 12-week study period. the incidence of flue and cold during the study period were compared between study groups. blood and fecal samples were collected at baseline and at the end of the intervention. fecal samples were collected for the secretory immunoglobulin a (siga) analysis. blood sample was drawn for interferon γ (ifn-γ), interleukin 4 (il-4), interleukin 10 (il-10), immunoglobulin a (iga), immunoglobulin g (igg) and immunoglobulin m (igm) analysis.


Eligibility criteria:
inclusion criteria: * male or female between 25 to 45 years old; * having caught the common cold or flu at least 4 to 6 times in the past calendar year; * signed the informed consent forms before entering the study; * fully understood the risks and potential benefits in participating this study. exclusion criteria: * were diagnosed with the decreased immunity caused by any diagnosed chronic illness; * having any gastrointestinal illness with medical treatment at the time of being enrolled; * having any diagnosed respiratory illness with similar symptoms as the common cold and flu; * currently taking any pain killer drug; * having received any vaccine for the upper respiratory infection within 6 months before enrollment; * having received any purgative drug or digestion related drug within 2 weeks before enrollment; * having taken any dairy product containing prebiotics and probiotics within 10 days before enrollment; * currently taking any preventive drug for upper respiratory infection; * having received any drug which has impact with the immune system such as antibiotics within 3 months before enrollment; * alcoholic or addicted to any drug; * pregnant or breastfeeding mothers; * having participated another clinical trial within 3 months before enrollment.
prognostic value of confocal endomicroscopy in ulcerative colitis: the conf-uc study

Conditions: Ulcerative Colitis

Summary: this study employs a prospective, single-center, interventional design to investigate the prognostic value of confocal endomicroscopy in assessing treatment response in ulcerative colitis (uc) patients receiving small molecules .

the study incorporates confocal endomicroscopy as an additional diagnostic modality for assessing barrier dysfunction and treatment response in uc patients. confocal endomicroscopy enables real-time visualization of mucosal changes at a cellular level during endoscopy, potentially enhancing the detection of treatment response and mucosal healing. eligible patients will undergo baseline assessment, including clinical evaluation, partial mayo score calculation, endoscopic evaluation, biopsies with histological evaluation and confocal endomicroscopy. follow-up assessments will be conducted at 8 weeks and 6 months after initiating therapy with small molecules . the study aims to enroll a sample size of 26 uc patients to pilot the feasibility and utility of confocal endomicroscopy in assessing barrier dysfunction and treatment response.

Eligibility criteria:
inclusion criteria: 1. established diagnosis of uc since at least 12 weeks prior to inclusion 2. age ≥ 18 years 3. any gender/sex 4. active disease consistent with indication to start with small molecules (defined as mayo endoscopic score (mes) ≥ 1, partial mayo score ≥ 3 (with at least rectal bleeding score of 1 and bowel movements score of 1) 5. no contraindications to endoscopy or confocal exam 6. ability to understand and to comply with the study procedure and sign an informed consent form exclusion criteria: 1. subjects with an endoscopic mayo sub-score at baseline \&lt;2; 2. pregnancy 3. subjects with any contraindication to any study procedure (included fluorescein allergy).